Exeliom’s Bacteria-Focused Approach To Immunotherapy

 
• By Janelle Hart

In Vivo sat down with Benjamin Hadida, CEO of Exeliom, at the 2024 BIO International Convention to discuss how the company is using its first-in-class drug candidate to improve therapeutic responsiveness in immuno-oncology, immuno-inflammation and rare disease. 

Three parallel trials drive forward a Bacteria-Focused approach to Immunotherapy • Source: Shutterstock

More from Innovation

More from In Vivo